Latest News & Updates

Breaking News

  • 9 hours ago

  • Vaibhavi M.

Takeda’s Phase 3 KEPLER Trial Shows ENTYVIO Achieves Remission, Demonstrates Efficacy And Safety In Pediatric Ulcerative Colitis
Breaking News
MoonLake Immunotherapeutics Delivers Strong Phase 2 Results For Sonelokimab In axSpA & Announces Solid 2025 Financial Performance

Simantini Singh Deo

FDA Accepts Roche’s NDA For Giredestrant Plus Everolimus In ESR1-Mutated ER-Positive Advanced Breast Cancer

Vaibhavi M.

AstraZeneca’s Calquence Plus Venetoclax Approved In US Based On Phase III AMPLIFY Trial Results, As First Fixed-Duration Oral Regimen For Chronic Lymphocytic Leukaemia (CLL) And Small Lymphocytic Lymphoma (SLL)

Vaibhavi M.

ImmunityBio Partners With Biopharma And Cigalah To Launch ANKTIVA In Saudi Arabia And Expand Across MENA, Secures Strategic Distribution Alliance

Vaibhavi M.

Other trending news you may like to read

Takeda’s Phase 3 KEPLER Trial Shows ENTYVIO Achieves Remission, Demonstrates Efficacy And Safety In Pediatric Ulcerative Colitis

Takeda’s Phase 3 KEPLER trial shows ENTYVIO achieves remission in pediatric ulcerative colitis.

Vaibhavi M.

Pharma Now

MoonLake Immunotherapeutics Delivers Strong Phase 2 Results For Sonelokimab In axSpA & Announces Solid 2025 Financial Performance

MoonLake reports strong Phase 2 sonelokimab results in axSpA and posts solid 2025 financial performance.

Simantini Singh Deo

Pharma Now

FDA Accepts Roche’s NDA For Giredestrant Plus Everolimus In ESR1-Mutated ER-Positive Advanced Breast Cancer

FDA accepts Roche’s NDA for giredestrant plus everolimus in ESR1-mutated ER-positive advanced breast cancer.

Vaibhavi M.

Pharma Now

AstraZeneca’s Calquence Plus Venetoclax Approved In US Based On Phase III AMPLIFY Trial Results, As First Fixed-Duration Oral Regimen For Chronic Lymphocytic Leukaemia (CLL) And Small Lymphocytic Lymphoma (SLL)

AstraZeneca’s Calquence plus venetoclax gains FDA approval as first fixed-duration oral regimen for CLL and SLL.

Vaibhavi M.

Pharma Now